Clinical Trial Update: A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a hemp-derived cannabidiol product for anxiety in glioblastoma patients was terminated, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Hemp-derived cannabidiol product (cannabidiol)

Snippet

Sponsor: Mclean Hospital | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2026-03-16